We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CDK4/6 Inhibitor

News List

G1 Therapeutics and Genor Biopharma sign agreement for Lerociclib expresspharma
June 24, 2020
As per the exclusive license agreement, Genor to lead clinical development, regulatory submissions and commercialisation of lerociclib in Asia-Pacific.
CStone registers for Phase I trial of CDK4/6 inhibitor CS3002 in Australia biospectrumasia
August 25, 2019
An open-label, multi-dose, dose-escalation, and dose-expansion Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumour efficacy of CS3002 in patients with advanced solid tumours
Lilly’s Verzenios approved by NICE pharmaphorum
January 21, 2019
NICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the NHS.